STAT+: UniQure’s gene therapy continues to slow Huntington’s progression after four years

AI Summary

UniQure reports that its gene therapy continued to slow the progression of Huntington’s disease over four years. However, the measured benefit was smaller than in an analysis published a year earlier.

UniQure's gene therapy continues to slow Huntington's progression after four years. But the magnitude of the benefit waned compared to a similar analysis from a year ago.